The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched by the World Health Organization (WHO) in 2000.
The Programme has two main components:
• interrupting transmission of lymphatic fi lariasis through mass drug administration, and
• managing morbidity and preventing disability.
Good progress was made with mass drug administration between 2000 and 2010, with over 3.9 billion doses of medicine delivered to a cumulative targeted population of 952 million people (1). Interventions to prevent and manage lymphatic filariasis-related disabilities in endemic communities were, however, limited.
In 2010, WHO published the GPELF progress report and strategic plan for the first 10 years of the Programme, with an outline of the approach and milestones for the second 10 years (2). One of the milestones is to disseminate revised.
This document provides guidance on planning, implementing and monitoring activities at national level. It provides the best available information on managing morbidity and preventing disability after acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or elephantiasis, and hydrocoele. It also provides general operational and managerial guidance for reducing the number of cases of lymphatic filariasis and providing care for those affected.
CY - Geneva LA - eng M1 - WHO/HTM/NTD/PCT/2013.7 M3 - report N2 -The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched by the World Health Organization (WHO) in 2000.
The Programme has two main components:
• interrupting transmission of lymphatic fi lariasis through mass drug administration, and
• managing morbidity and preventing disability.
Good progress was made with mass drug administration between 2000 and 2010, with over 3.9 billion doses of medicine delivered to a cumulative targeted population of 952 million people (1). Interventions to prevent and manage lymphatic filariasis-related disabilities in endemic communities were, however, limited.
In 2010, WHO published the GPELF progress report and strategic plan for the first 10 years of the Programme, with an outline of the approach and milestones for the second 10 years (2). One of the milestones is to disseminate revised.
This document provides guidance on planning, implementing and monitoring activities at national level. It provides the best available information on managing morbidity and preventing disability after acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or elephantiasis, and hydrocoele. It also provides general operational and managerial guidance for reducing the number of cases of lymphatic filariasis and providing care for those affected.
PB - WHO PP - Geneva PY - 2013 SN - 978 92 4 150529 1 EP - 69 p. TI - Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme. UR - http://apps.who.int/iris/bitstream/10665/85347/1/9789241505291_eng.pdf ER -